Published in J Pediatr on July 17, 2012
Skeletal muscle denervation causes skeletal muscle atrophy through a pathway that involves both Gadd45a and HDAC4. Am J Physiol Endocrinol Metab (2013) 1.17
Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trial. PLoS One (2015) 0.90
The Genetics of Spinal Muscular Atrophy: Progress and Challenges. Neurotherapeutics (2015) 0.86
Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res (2016) 0.84
Congenital and childhood myotonic dystrophy: Current aspects of disease and future directions. World J Clin Pediatr (2015) 0.84
Spinal muscular atrophy: from tissue specificity to therapeutic strategies. F1000Prime Rep (2015) 0.82
A mixed methods exploration of families' experiences of the diagnosis of childhood spinal muscular atrophy. Eur J Hum Genet (2014) 0.81
Emerging therapies and challenges in Spinal Muscular Atrophy. Ann Neurol (2016) 0.80
Axonal Excitability in Amyotrophic Lateral Sclerosis : Axonal Excitability in ALS. Neurotherapeutics (2016) 0.79
Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool. PLoS One (2017) 0.75
Amyotrophic lateral sclerosis. Lancet (2011) 5.86
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
GJB2 mutations and degree of hearing loss: a multicenter study. Am J Hum Genet (2005) 2.63
Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol (2013) 2.52
Guillain-Barré syndrome: an update. J Clin Neurosci (2009) 2.46
Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol (2009) 2.20
Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol (2011) 2.08
Botulinum toxin modulates cortical maladaptation in post-stroke spasticity. Muscle Nerve (2013) 2.00
Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain (2008) 1.94
Isolated bulbar phenotype of amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2011) 1.75
The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. Hum Mol Genet (2010) 1.73
Segmental facial anhidrosis and tonic pupils with preserved deep tendon reflexes: a novel autonomic neuropathy. J Neuroophthalmol (2005) 1.63
Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol (2011) 1.59
The time of our lives: life span development of timing and event tracking. J Exp Psychol Gen (2006) 1.57
Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch Neurol (2011) 1.55
Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis. Clin Neurophysiol (2008) 1.54
Split-hand index for the diagnosis of amyotrophic lateral sclerosis. Clin Neurophysiol (2012) 1.52
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain (2009) 1.50
Changes in human sensory axonal excitability induced by an ischaemic insult. Clin Neurophysiol (2008) 1.49
Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clin Neurophysiol (2012) 1.49
Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain (2006) 1.47
Corticomotoneuronal function in asymptomatic SOD-1 mutation carriers. Clin Neurophysiol (2010) 1.47
FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry (2009) 1.44
Riluzole: a glimmer of hope in the treatment of motor neurone disease. Med J Aust (2005) 1.42
Regional differences in ulnar nerve excitability may predispose to the development of entrapment neuropathy. Clin Neurophysiol (2010) 1.41
Differentiating patterns of oligoclonal banding in the cerebrospinal fluid improves diagnostic utility for multiple sclerosis. Pathology (2012) 1.41
Scurvy and stroke - is there an association? Med J Aust (2010) 1.40
Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve (2005) 1.37
Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol (2009) 1.37
Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin (2014) 1.36
Neurotoxic marine poisoning. Lancet Neurol (2005) 1.33
Motor neuron dysfunction in frontotemporal dementia. Brain (2011) 1.31
Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve (2007) 1.30
Axonal ion channels from bench to bedside: a translational neuroscience perspective. Prog Neurobiol (2009) 1.27
Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist (2011) 1.22
Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol (2006) 1.22
Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis. Curr Mol Med (2009) 1.19
Dystrophin gene mutation location and the risk of cognitive impairment in Duchenne muscular dystrophy. PLoS One (2010) 1.19
Fatigue in multiple sclerosis: mechanisms and management. Clin Neurophysiol (2010) 1.18
Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis? Amyotroph Lateral Scler (2012) 1.18
Altered nerve excitability properties in established diabetic neuropathy. Brain (2005) 1.17
Assessment of cortical excitability using threshold tracking techniques. Muscle Nerve (2006) 1.17
Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum. PLoS One (2012) 1.15
Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. J Neurol Neurosurg Psychiatry (2012) 1.14
Activity-dependent excitability changes suggest Na+/K+ pump dysfunction in diabetic neuropathy. Brain (2008) 1.10
FOSMN syndrome: novel insight into disease pathophysiology. Neurology (2012) 1.10
How common are behavioural changes in amyotrophic lateral sclerosis? Amyotroph Lateral Scler (2010) 1.09
Amyotrophic lateral sclerosis and frontotemporal dementia: A behavioural and cognitive continuum. Amyotroph Lateral Scler (2012) 1.08
Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2007) 1.05
Changes in human sensory axonal excitability induced by focal nerve compression. J Physiol (2010) 1.04
Altered motor nerve excitability in end-stage kidney disease. Brain (2005) 1.02
Oxaliplatin and axonal Na+ channel function in vivo. Clin Cancer Res (2006) 1.00
Nerve function and dysfunction in acute intermittent porphyria. Brain (2008) 1.00
Engaging in patient decision-making in multidisciplinary care for amyotrophic lateral sclerosis: the views of health professionals. Patient Prefer Adherence (2012) 1.00
Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer (2012) 0.98
Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2007) 0.98
Treatment of proximal upper limb tremor with botulinum toxin therapy. Mov Disord (2013) 0.97
Population screening and cascade testing for carriers of SMA. Eur J Hum Genet (2007) 0.97
INSPIRATIonAL--INSPIRAtory muscle training in amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2009) 0.96
Measurement of the clinical utility of a combined mutation detection protocol in carriers of Duchenne and Becker muscular dystrophy. J Med Genet (2007) 0.96
Upregulation of persistent sodium conductances in familial ALS. J Neurol Neurosurg Psychiatry (2009) 0.95
Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. Brain (2010) 0.95
Quantifying disease progression in amyotrophic lateral sclerosis. Ann Neurol (2014) 0.94
Threshold behaviour of human axons explored using subthreshold perturbations to membrane potential. J Physiol (2008) 0.94
Axonal changes in spinal cord injured patients distal to the site of injury. Brain (2007) 0.94
Neurological complications of chronic kidney disease. Nat Rev Neurol (2009) 0.93
Has potassium been prematurely discarded as a contributing factor to the development of uraemic neuropathy? Nephrol Dial Transplant (2004) 0.93
Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain (2013) 0.92
Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity. PLoS One (2011) 0.92
Pathophysiological insights into ALS with C9ORF72 expansions. J Neurol Neurosurg Psychiatry (2013) 0.92
Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. Ann Neurol (2014) 0.91
Assessment of disease progression in motor neuron disease. Lancet Neurol (2005) 0.91
The floppy weak infant revisited. Brain Dev (2003) 0.91
Neurophysiological index as a biomarker for ALS progression: validity of mixed effects models. Amyotroph Lateral Scler (2011) 0.91
Cortical atrophy in ALS is critically associated with neuropsychiatric and cognitive changes. Neurology (2013) 0.90
Congenital myasthenic syndromes. J Clin Neurosci (2008) 0.90
Assessing the accuracy of a combination of clinical tests for identifying carpal tunnel syndrome. J Clin Neurosci (2009) 0.90
The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform. PLoS One (2013) 0.90
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. PLoS One (2013) 0.89
The case of a 48 year-old woman with bizarre and complex delusions. Nat Rev Neurol (2010) 0.89
Assessment of nerve excitability in toxic and metabolic neuropathies. J Peripher Nerv Syst (2008) 0.88
Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle Nerve (2010) 0.88
Puffer fish poisoning: a potentially life-threatening condition. Med J Aust (2002) 0.88
Riluzole therapy for motor neurone disease: an early Australian experience (1996-2002). J Clin Neurosci (2006) 0.87
Predicting a positive response to intravenous immunoglobulin in isolated lower motor neuron syndromes. PLoS One (2011) 0.87
The effects of alterations in conditioning stimulus intensity on short interval intracortical inhibition. Brain Res (2009) 0.87
The puzzling case of hyperexcitability in amyotrophic lateral sclerosis. J Clin Neurol (2013) 0.86